Comparative Pharmacology
Head-to-head clinical analysis: EULEXIN versus NILUTAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EULEXIN versus NILUTAMIDE.
EULEXIN vs NILUTAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone to androgen receptors in target tissues, thereby blocking androgen action.
Nonsteroidal antiandrogen that competitively inhibits androgen binding to androgen receptors, blocking androgen action in target tissues.
250 mg orally three times daily (every 8 hours).
300 mg orally once daily
None Documented
None Documented
5-6 hours for flutamide; 8-10 hours for active metabolite 2-hydroxyflutamide; requires three times daily dosing
The terminal elimination half-life is approximately 38–56 hours (mean ~49 hours), allowing once-daily dosing. Steady-state is achieved after about 7–10 days.
Clinical Note
moderateNilutamide + Digoxin
"Nilutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilutamide + Digitoxin
"Nilutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilutamide + Deslanoside
"Nilutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilutamide + Acetyldigitoxin
"Nilutamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Renal: 28% (as unchanged drug and metabolites, mainly 2-hydroxyflutamide), Biliary/Fecal: 4.2% (as metabolites)
Nilutamide is extensively metabolized; less than 2% of the dose is excreted unchanged in urine. The majority of metabolites (approximately 70%) are excreted renally, with the remainder (about 30%) eliminated in feces via biliary excretion.
Category C
Category C
Antiandrogen
Antiandrogen